JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
FREE Shipping for orders over $200
Finasteride is an inhibitor of 5 alpha-reductase, an enzyme responsible for the conversion of testosterone into its more potent form dihydrotestosterone (DHT). DHT is known to contribute to the enlargement of the prostate gland in benign prostatic hyperplasia. Further, it causes miniaturization of hair follicles, leading to androgenetic alopecia. By reducing the production of DHT, finasteride treats benign prostatic hyperplasia (BPH) and male pattern hair loss.
Finasteride was first approved by the FDA under the brand name Proscar in 1992 for the treatment of BPH. In 1997, the FDA expanded its approval under the brand name Propecia for androgenetic alopecia treatment. At present, it is being studied for its effect on sleep apnea. On our website, finasteride purchase is exclusively limited to research and educational purposes.
From Pubchem
IUPAC Name:(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamideSynonyms: Proscar, Propecia, FinastidMolecular Formula: C23H36N2O2Molecular Weight: 372.5 g/molCAS Number: 98319-26-7PubChem CID: 57363
Finasteride inhibits the conversion of testosterone into dihydrotestosterone, a primary androgen in the prostate tissue. Research shows its effectiveness in reducing the risk of prostate cancer. In the Prostate Cancer Prevention Trial (PCPT), 18, 882 men with prostate-specific antigen (PSA) levels of 3ng per milliliter were randomized to receive 5mg finasteride or placebo per day for seven years. The results found that the relative risk of prostate cancer in the treatment group was 24.8% lower than that in placebo. Furthermore, an increased risk of high-grade prostate cancer with finasteride was observed, leading to recommendations against its use for prostate cancer prevention[1].
Researchers conclude that the increase in high-grade cancers linked to finasteride in the PCPT might be more related to its impact on prostate size and its selective inhibition of low-grade cancer, rather than its influence on tumor appearance. Plus, high-grade cancer was detected earlier and was less widespread in the finasteride group compared to the placebo group [2].
Finasteride is used to treat male pattern baldness, also known as androgenetic alopecia. Research shows that finasteride treatment prevents further hair loss and brings about a 30% improvement in hair loss after 6 months of therapy [3].
Its systemic use is associated with side effect that limits its long-term utilization. A study showed that topical finasteride decreased the levels of dihydrotestosterone in both scalp and blood plasma. Moreover, it caused a reduction in the rate of hair loss and increased total and terminal hair count [4]. Finasteride has also been studied for female pattern alopecia but the results were not superior to placebo [5].
In female-to-male transgender patients, androgen therapy can cause the development of androgenetic alopecia. One study was conducted to look at the effects of oral finasteride on androgenetic alopecia in transgender patients. Ten patients with AGA took 1 mg of oral finasteride for at least 12 months. The results found AGA improvement by one grade on the Norwood-Hamilton scale in all patients after 5.5 months of treatment, with no significant adverse effects [6].
Finasteride has been shown to be effective for the treatment of hirsutism. Hirsutism, characterized by excessive facial or body hair, is often caused by increased levels of androgen in the body. One study was conducted to determine the effectiveness of finasteride for the treatment of idiopathic hirsutism and hirsutism in women with PCOS. Participants daily received 5mg of the drug for a period of six months. The researchers found finasteride to be effective and well-tolerated in both diseased groups [7].
Central Serous Retinopathy (CSR) is an idiopathic disorder characterized by the accumulation of fluid under the retina, causing serous detachment and vision loss. Its pathophysiology involves choroidal vasculature hyperpermeability, leading to retinal pigment epithelial detachments and fluid accumulation. Glucocorticoids and elevated testosterone levels are associated with CSC, and anti-glucocorticosteroid agents like finasteride, which inhibits testosterone conversion, might be a suitable treatment option [8].
In a small-size study, five patients with chronic CSR were administered 5mg of finasteride daily for 3 months. After that, the medicine was withheld and patients were observed for three months. Researchers found that mean BCVA (best-corrected visual acuity) remained unchanged. Center-subfield macular thickness and subretinal fluid volume initially decreased, correlated with serum DHT levels, and returned below baseline after 6 months. Discontinuing finasteride affected some patients' macular thickness and fluid volume, but one patient's parameters remained stable even post-medication [9].
Finasteride inhibits the enzyme, 5 alpha-reductase, responsible for the conversion of testosterone into dihydrotestosterone. It is approved by the FDA for the treatment of benign prostatic hyperplasia and androgenetic alopecia. Research shows that it might be beneficial for the treatment of hirsutism and central serous chorioretinopathy. We need more research to confirm its efficacy and safety for these conditions. At Element Sarms, liquid finasteride for sale is exclusively available for research and educational institutions. Only buy finasteride if you are a qualified researcher.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.